Organization | Novonesis

Novonesis Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Bagsvaerd Denmark (1925)

Organization Overview

First Clinical Trial

2021

NCT04767789

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Novozymes A/S

Active Ingredients

Drugs in Phase 4 Trials (2)

Key: Novonesis (0) Acquired (2)

bifidobacterium animalis (7 trials)

xylitol (1 trial)

Drugs in Phase 3 Trials (3)

Key: Novonesis (0) Acquired (3)

autologous microbiome (2 trials)

esomeprazole (nexium) (1 trial)

lactobacillus casei (2 trials)

Drugs in Phase 2 Trials (2)

Key: Novonesis (0) Acquired (2)

chickpea (1 trial)

lactobacillus reuteri (8 trials)

Drugs in Phase 1 Trials (3)

Key: Novonesis (0) Acquired (3)

Lactobacillus amylovorus (1 trial)

lactobacillus fermentum (1 trial)

lactobacillus rhamnosus (5 trials)

Drugs in Other Trials (16)

Key: Novonesis (4) Acquired (12)

arginine (1 trial)

bacillus velezensis dsm 33864 (1 trial)

bif-038 (1 trial)

bifidobacteria adolescentis bd1 (1 trial)

bifidobacterium breve (6 trials)

bifidobacterium lactis (1 trial)

bifidobacterium rhamnosus (1 trial)

human milk (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus delbrueckii (2 trials)

lactobacillus gasseri (1 trial)

lactobacillus helveticus (1 trial)

lactobacillus plantarum (2 trials)

Limosilactocillus Reuteri (1 trial)

maltose (1 trial)

polyphenol oxidase (1 trial)

Indications

Overview

Highest Phase: Phase 0
# of Trials: 40
# of Trial APIs: 26